Factors Associated with Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial
Authors:
- Danyal IbrahimDIDanyal Ibrahim
- Latha DulipsinghLDLatha Dulipsingh
- Lisa ZapatkaLZLisa Zapatka
- Reginald EadieREReginald Eadie
- Rebecca CrowellRCRebecca Crowell
- Kendra WilliamsKWKendra Williams
- Dorothy B. WakefieldDWDorothy B. Wakefield
- Lisa CookLCLisa Cook
- Jennifer PuffJPJennifer Puff
- Syed A. HussainSHSyed A. Hussain
Preprint
Abstract
We conducted a prospective single-arm open-label phase II clinical trial assessing the safety and efficacy of convalescent plasma in hospitalized COVID-19 patients. Convalescent plasma with sufficient IgG titer (1:320) obtained from recovered donors was administered to adult patients with either severe or critical COVID-19 illness. Primary outcomes were adverse events in association with plasma administration, and hospital mortality. Secondary outcomes included disease progression, recovery, length of stay, and hospital discharge. Of the 38 patients included in the analysis, 24 (63%) recovered and were discharged, and 14 (37%) died. Patients who received convalescent plasma early in the disease course (severe illness group) as compared to the patients that received convalescent plasma later in disease progression (critical illness group) had significantly lower hospital mortality 13% vs 55% (p<0.02) and shorter mean hospital length of stay 15.4 vs 33 days (p<0.01). One patient experienced a transient transfusion reaction. No other adverse effects of convalescent plasma infusion were observed. Our results suggest that convalescent plasma is safe and has the potential for positive impact on clinical outcomes including recovery and survival if given to patients early in the course of COVID-19 disease.Keywords
All Related Versions
- Published version: Infectious Diseases and Therapy, 9 (4), 913.
This publication has 14 references indexed in Scilit:
- Hydroxychloroquine, Coronavirus Disease 2019, and QT ProlongationJAMA Cardiology, 2020
- Clinical progression of patients with COVID-19 in Shanghai, ChinaJournal of Infection, 2020
- Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19Aging, 2020
- Effectiveness of convalescent plasma therapy in severe COVID-19 patientsProceedings of the National Academy of Sciences, 2020
- A New Symptom of COVID‐19: Loss of Taste and SmellObesity, 2020
- A Systematic Review of COVID-19 Epidemiology Based on Current EvidenceJournal of Clinical Medicine, 2020
- Clinical and immunological features of severe and moderate coronavirus disease 2019Journal of Clinical Investigation, 2020
- Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective studyChinese Medical Journal, 2020
- Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus diseaseChinese Medical Journal, 2020
- The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysisThe Journal of Infectious Diseases, 2014